JDRF, Sanofi expand research collaboration for insulin-dependent diabetes

Tuesday, March 1, 2016

JDRF, a global organization funding and advocating for type 1 diabetes (T1D) research, and Sanofi U.S. Services, a subsidiary of Sanofi, have entered into new agreements with four research organizations under their joint research collaboration to support development of glucose responsive insulins (GRIs), an alternate class of therapies that is expected to improve the treatment of insulin-dependent diabetes, particularly T1D.

[Read More]

Congress approves one-year renewal diabetes research funding

Wednesday, April 2, 2014

The U.S. Senate has approved legislation for a one-year extension of the Special Diabetes Program (SDP)—an initiative that accounts for roughly one-third of all federally funded type 1 diabetes (T1D) research in the U.S. The decision comes on the heels of the March 27 approval of the legislation by the U.S. House of Representatives, and will extend SDP funding for the National Institutes of Health (NIH) at the current level of $150 million, as part of the “Protecting Access to Medicare Act of 2014.”

[Read More]